Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Newly customized cationic ẞ-cyclodextrins as potential nanovectors for gene delivery.

International journal of pharmaceutics·2026
Same author

Targeting sialic acid catabolism with polyvalent sialidase inhibitors to mitigate bacterial inflammation in the gut.

Bioorganic chemistry·2025
Same author

Polyphosphazene-Based Nanotherapeutics.

Journal of functional biomaterials·2025
Same author

Designing polyphosphazene derivatives for gene delivery in glioblastoma treatment.

Materials today. Bio·2025
Same author

Protamine nanocapsules as gene delivery carriers for the treatment of intraocular tumors.

Drug delivery and translational research·2025
Same author

Mutagenesis to Orient Conjugation and Preserve Self-adjuvant Properties of Flagellin in Conjugates.

Chembiochem : a European journal of chemical biology·2025

Related Experiment Video

Updated: Nov 15, 2025

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain
08:07

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain

Published on: July 25, 2022

2.8K

A chitosan-based nanosystem as pneumococcal vaccine delivery platform.

Sandra Robla1,2, Maruthi Prasanna1,3, Rubén Varela-Calviño4

  • 1Center for Research in Molecular Medicine and Chronic Diseases, University of Santiago de Compostela, A Coruña, Spain.

Drug Delivery and Translational Research
|March 3, 2021
PubMed
Summary

Chitosan nanocapsules conjugated with Streptococcus pneumoniae PsaA antigen show potential for nasal vaccines. This system enhances immune cell uptake and T-cell activation, promising a robust adaptive immune response against pneumococcus.

Keywords:
Antigen proteinChitosanDendritic cellImmune responseNanovaccine

More Related Videos

Production of Near-Infrared Sensitive, Core-Shell Vaccine Delivery Platform
06:27

Production of Near-Infrared Sensitive, Core-Shell Vaccine Delivery Platform

Published on: October 20, 2020

5.5K
Preparation and Characterization of SDF-1α-Chitosan-Dextran Sulfate Nanoparticles
12:00

Preparation and Characterization of SDF-1α-Chitosan-Dextran Sulfate Nanoparticles

Published on: January 22, 2015

12.7K

Related Experiment Videos

Last Updated: Nov 15, 2025

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain
08:07

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain

Published on: July 25, 2022

2.8K
Production of Near-Infrared Sensitive, Core-Shell Vaccine Delivery Platform
06:27

Production of Near-Infrared Sensitive, Core-Shell Vaccine Delivery Platform

Published on: October 20, 2020

5.5K
Preparation and Characterization of SDF-1α-Chitosan-Dextran Sulfate Nanoparticles
12:00

Preparation and Characterization of SDF-1α-Chitosan-Dextran Sulfate Nanoparticles

Published on: January 22, 2015

12.7K

Area of Science:

  • Biomaterials Science
  • Vaccinology
  • Immunology

Background:

  • Chitosan nanosystems are effective for antigen delivery and enhancing nasal vaccine immunogenicity.
  • The Streptococcus pneumoniae cell membrane protein PsaA is a common antigen across all pneumococcal serotypes.

Purpose of the Study:

  • To develop chitosan nanocapsules chemically conjugated with PsaA for nasal vaccine delivery.
  • To evaluate the immunogenicity and immune cell activation potential of PsaA-conjugated nanocapsules.

Main Methods:

  • Chitosan nanocapsules were synthesized using thiol-maleimide conjugation for PsaA surface presentation.
  • Characterization included particle size, charge, stability in simulated nasal fluid, and PsaA association rates.
  • In vitro studies assessed cytotoxicity, dendritic cell maturation, T-cell activation (CD4+, CD8+), and cytokine secretion (TNFα).

Main Results:

  • Spherical nanocapsules (266 ± 32 nm) with positive charge (+30 ± 1 mV) and good stability (24h) were produced.
  • Covalent conjugation significantly increased PsaA association rates (3x higher).
  • Nanocapsules demonstrated low cytotoxicity (<150 µg/mL), induced dendritic cell maturation, and activated CD4+ and CD8+ T lymphocytes, with TNFα secretion observed.

Conclusions:

  • Chitosan-PsaA nanocapsules are a promising platform for nasal vaccines against Streptococcus pneumoniae.
  • The system effectively enhances antigen presentation, immune cell uptake, and adaptive T-cell responses.
  • Further development could lead to novel, effective, and non-toxic pneumococcal vaccines.